2026-04-17T11:50:22Zhttps://recercat.cat/oai/requestoai:recercat.cat:2072/4690352025-10-27T10:59:10Zcom_2072_98col_2072_378192
Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease : An international overview
Delaby, Constance
Teunissen, Charlotte E.
Blennow, Kaj
Alcolea, Daniel
Arisi, Ivan
Amar, Elodie Bouaziz
Beaume, Anne
Bedel, Aurelie
Bellomo, Giovanni
Bigot-Corbel, Edith
Bjerke, Maria
Blanc-Quintin, Marie-Céline
Boada, Mercè
Bousiges, Olivier
Chapman, Miles D
DeMarco, Mari L.
D'Onofrio, Mara
Dumurgier, Julien
Dufour-Rainfray, Diane
Engelborghs, Sebastiaan
Esselmann, Hermann
Fogli, Anne
Gabelle, Audrey
Galloni, Elisabetta
Gondolf, Clémentine
Grandhomme, Frédérique
Grau-Rivera, Oriol
Hart, Melanie
Ikeuchi, Takeshi
Jeromin, Andreas
Kasuga, Kensaku
Keshavan, Ashvini
Khalil, Michael
Körtvelyessy, Peter
Kulczynska-Przybik, Agnieszka
Laplanche, Jean-Louis
Lewczuk, Piotr
Li, Qiao-Xin
Lleó, Alberto
Malaplate, Catherine
Marquié, Marta
Masters, Colin L.
Mroczko, Barbara
Nogueira, Léonor
Orellana, Adelina
Otto, Markus
Oudart, Jean-Baptiste
Paquet, Claire
Paoletti, Federico Paolini
Parnetti, Lucilla
Perret-Liaudet, Armand
Peoc'h, Katell
Poesen, Koen
Puig-Pijoan, Albert
Quadrio, Isabelle
Quillard-Muraine, Muriel
Rucheton, Benoit
Schraen, Susanna
Schott, Jonathan M.
Shaw, Leslie M.
Suárez-Calvet, Marc
Tsolaki, Magda
Tumani, Hayrettin
Udeh-Momoh, Chinedu
Vaudran, Lucie
Verbeek, Marcel M
Verde, Federico
Vermunt, Lisa
Vogelgsang, Jonathan
Wiltfang, Jens
Zetterberg, Henrik
Lehmann, Sylvain
Universitat Autònoma de Barcelona
Alzheimer's disease
Cerebrospinal fluid biomarkers
Clinical report
Consensus approach
Harmonization
The current practice of quantifying cerebrospinal fluid (CSF) biomarkers as an aid in the diagnosis of Alzheimer's disease (AD) varies from center to center. For a same biochemical profile, interpretation and reporting of results may differ, which can lead to misunderstandings and raises questions about the commutability of tests. We obtained a description of (pre-)analytical protocols and sample reports from 40 centers worldwide. A consensus approach allowed us to propose harmonized comments corresponding to the different CSF biomarker profiles observed in patients. The (pre-)analytical procedures were similar between centers. There was considerable heterogeneity in cutoff definitions and report comments. We therefore identified and selected by consensus the most accurate and informative comments regarding the interpretation of CSF biomarkers in the context of AD diagnosis. This is the first time that harmonized reports are proposed across worldwide specialized laboratories involved in the biochemical diagnosis of AD.
2021
Article
Instituto de Salud Carlos III PI18/00435
Instituto de Salud Carlos III PI17/01474
Instituto de Salud Carlos III PI17/01896
Instituto de Salud Carlos III PI19/00335
Instituto de Salud Carlos III PI19/00155
Alzheimer's & dementia ; Vol. 18 (december 2021), p. 1868-1879
open access
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
https://creativecommons.org/licenses/by-nc-nd/4.0/